Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC combined with donafenib and camrelizumab for unresectable hepatocellular carcinoma with main portal vein tumor thrombus
ChiCTR2100051714Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib, camrelizumab and durvalumab + lenvatinib + gemcitabine + cisplatin in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Objective response rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
donafenibcamrelizumabdurvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100051714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051714.